What’s next for specialty? Seven predictions for 2016

2015 is in the rearview mirror, and in many ways, it was a year like no other for the specialty pharmaceutical...

Read More

Biosimilars: meet 2016’s solution to the specialty drug cost conundrum

If you work in the pharma or biotech industry, you’ve probably heard the buzz about biosimilars. And, there’s a good...

Read More
Page 1 of 1